FS Development Corp. II (FSII): Price and Financial Metrics
GET POWR RATINGS... FREE!
FSII Stock Price Chart Interactive Chart >
FSII Price/Volume Stats
|Current price||$9.80||52-week high||$15.05|
|Prev. close||$10.00||52-week low||$9.64|
|Day high||$10.16||Avg. volume||99,758|
|50-day MA||$11.64||Dividend yield||N/A|
|200-day MA||$10.43||Market Cap||203.12M|
FS Development Corp. II (FSII) Company Bio
FS Development Corp. II operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Most Popular Stories View All
FSII Latest News Stream
|Loading, please wait...|
FSII Latest Social Stream
View Full FSII Social Stream
Latest FSII News From Around the Web
Below are the latest news stories about FS Development Corp II that investors may wish to consider to help them evaluate FSII as an investment opportunity.
Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19
Pardes Biosciences Main Protease Pardes Biosciences Main Protease PBI-0451 Pardes Biosciences PBI-0451 Oral Antiviral Pill Pardes NASDAQ Listing Pardes Biosciences Debuts on NASDAQ PRDS Nasdaq Listed Pardes Biosciences debuts on NASDAQ under ticker symbol "PRDS" Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million, combining approximately $199 million of fund
The small company, formed as the Covid pandemic started to take hold in February 2020, could take its oral drug into a late-stage clinical trial as early as the first half of next year.
FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections
SAN FRANCISCO & LARKSPUR, Calif., December 21, 2021--FSII and Pardes Biosciences move towards merger with the goal of tackling COVID-19 via an oral antiviral.
Shares of FS Development Corp. II (NASDAQ:FSII) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $10.79. FS Development Corp. II shares last traded at $10.79, with a volume of 169,882 shares changing hands. The businesss 50 day moving 
FS Development Corp. II (NASDAQ:FSII) Share Price Crosses Above Two Hundred Day Moving Average of $0.00
FS Development Corp. II (NASDAQ:FSII)s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $10.79. FS Development Corp. II shares last traded at $10.79, with a volume of 169,882 shares changing hands. The stocks 50 day simple 
FSII Price Returns